Heart disease
Conditions
Interventions
Self-management (experimental group):Require self-monitoring of INR at home every 1-2 weeks, self-adjustment of medication, and uploading of records to the remote anticoagulation follow-up platform
usual care group (control group):No intervention, regular doctor's visits
Sponsors
The Second Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Control patients: 1) Previously enrolled in the SMART study and will continue to be treated with warfarin for the next 12 months and will continue to have their INR reviewed in the outpatient clinic; 2) TTR > 45% in the previous year; 3) Compliance with the study protocol; 4) signing the informed consent form. Patients in the experimental group: 1) Previously participated in the PST group of the SMART study and will continue to take warfarin for treatment in the next 12 months, participated in the training related to self-management and passed the relevant examination, and will be engaged in warfarin self-management; 2) TTR > 45% in the previous year; 3) Obedience to the study protocol; 4) signing the informed consent form.
Exclusion criteria
Exclusion criteria: 1) is pregnant or has plans to become pregnant in the next 6 months; 2) hospitalisation for a major bleeding or embolic adverse event in the past 6 months 3) advanced renal failure (on haemodialysis or with glomerular clearance <10mL/min); 4) Alzheimer's disease or schizophrenia; 5) undergoing anti-cancer treatment; 6) has congestive heart failure and requires medication; 7) a history of bleeding, such as gastric ulcers 8) concurrently taking antiplatelet drugs such as aspirin. 9) Previous TTR=45%.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time in therapeutic range (TTR); | — |
Secondary
| Measure | Time frame |
|---|---|
| serious adverse events; | — |
Countries
China
Contacts
Public ContactShenglan Tan
The Second Xiangya Hospital of Central South University
Outcome results
None listed